Literature DB >> 28181674

Population-based study on resection rates and survival in patients with colorectal liver metastasis in Norway.

J-H Angelsen1,2, A Horn1, H Sorbye3,4, G E Eide5,6, I M Løes3,4, A Viste1,2.   

Abstract

BACKGROUND: Detailed knowledge about the proportion of patients with colorectal liver metastases (CLM) undergoing resection is sparse. The aim of this study was to analyse cumulative resection rates and survival in patients with CLM.
METHODS: For this population-based study of patients developing CLM during 2011-2013, data were extracted from the Norwegian Patient Registry and the Cancer Registry of Norway.
RESULTS: A total of 2960 patients had CLM; their median overall survival was 10·9 months. Liver resection was performed in 538 patients. The cumulative resection rate was 20·0 per cent. The cumulative resection rate was 23·3 per cent in patients aged less than 40 years, 31·1 per cent in patients aged 40-59 years, 24·7 per cent in those aged 60-74 years, 17·9 per cent in those aged 75-79 years and 4·7 per cent in patients aged 80 years or more (P < 0·001). In multivariable analysis, resection rate was associated with age, extrahepatic metastases, disease-free interval and geographical region. Overall survival after diagnosis of CLM was affected by liver resection (hazard ratio (HR) 0·54, 95 per cent c.i. 0·34 to 0·86), rectal cancer (HR 0·82, 0·74 to 0·90), metachronous disease (HR 0·66, 0·60 to 0·74), increasing age (HR 1·32, 1·28 to 1·37), region, and extrahepatic metastases (HR 1·90, 1·74 to 2·07). Three- and 4-year overall survival rates after hepatectomy were 73·2 and 54·8 per cent respectively.
CONCLUSION: The cumulative resection rate in patients with CLM in Norway between 2011 and 2013 was 20 per cent. Resection rates varied across geographical regions, and with patient and disease characteristics.
© 2017 BJS Society Ltd Published by John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2017        PMID: 28181674     DOI: 10.1002/bjs.10457

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  13 in total

1.  Contemporary practice and short-term outcomes after liver resections in a complete national cohort.

Authors:  Kristoffer Lassen; Linn Såve Nymo; Frank Olsen; Kristoffer Watten Brudvik; Åsmund Avdem Fretland; Kjetil Søreide
Journal:  Langenbecks Arch Surg       Date:  2018-12-05       Impact factor: 3.445

2.  Association between the lymph node ratio and hepatic tumor burden: importance for resectable colorectal liver metastases?

Authors:  Kristoffer Watten Brudvik; Kjetil Søreide
Journal:  Hepatobiliary Surg Nutr       Date:  2018-06       Impact factor: 7.293

3.  Disparities in resection of hepatic metastases in colon cancer.

Authors:  Madalyn G Neuwirth; Andrew J Epstein; Giorgos C Karakousis; Ronac Mamtani; E Carter Paulson
Journal:  J Gastrointest Oncol       Date:  2018-02

4.  Incidence of Liver Resection Following the Introduction of Caseload Requirements for Liver Surgery in Switzerland.

Authors:  Fabian Haak; Savas Soysal; Elisabeth Deutschmann; Giusi Moffa; Heiner C Bucher; Max Kaech; Christoph Kettelhack; Otto Kollmar; Marco von Strauss Und Torney
Journal:  World J Surg       Date:  2022-03-16       Impact factor: 3.282

5.  Systematic failure to operate on colorectal cancer liver metastases in California.

Authors:  Mustafa Raoof; Zeljka Jutric; Sidra Haye; Philip H G Ituarte; Beiqun Zhao; Gagandeep Singh; Laleh Melstrom; Susanne G Warner; Bryan Clary; Yuman Fong
Journal:  Cancer Med       Date:  2020-07-20       Impact factor: 4.452

6.  Synchronous and metachronous liver metastases in patients with colorectal cancer-towards a clinically relevant definition.

Authors:  Jennie Engstrand; Cecilia Strömberg; Henrik Nilsson; Jacob Freedman; Eduard Jonas
Journal:  World J Surg Oncol       Date:  2019-12-26       Impact factor: 2.754

7.  Genomic and prognostic heterogeneity among RAS/BRAFV600E /TP53 co-mutated resectable colorectal liver metastases.

Authors:  Kaja C G Berg; Tuva H Brunsell; Anita Sveen; Sharmini Alagaratnam; Merete Bjørnslett; Merete Hektoen; Kristoffer W Brudvik; Bård I Røsok; Bjørn Atle Bjørnbeth; Arild Nesbakken; Ragnhild A Lothe
Journal:  Mol Oncol       Date:  2021-01-08       Impact factor: 6.603

8.  Neoadjuvant Chemotherapy Followed by Radiofrequency Ablation Prolongs Survival for Ablatable Colorectal Liver Metastasis: A Propensity Score Matching Comparative Study.

Authors:  Yizhen Chen; Youyao Xu; Linwei Xu; Fang Han; Yurun Huang; Hang Jiang; Jia Wu; Yuhua Zhang
Journal:  Front Oncol       Date:  2021-10-22       Impact factor: 6.244

9.  Neoadjuvant chemotherapy and radiotherapy followed by resection/ablation in stage IV rectal cancer patients with potentially resectable metastases.

Authors:  Rongzhen Li; Qiaoxuan Wang; Bin Zhang; Weiwei Xiao; Yuanhong Gao; Yan Yuan; Weihao Xie; Xiaoxue Huang; Chengjing Zhou; Shu Zhang; Shaoqing Niu; Hui Chang; Dongni Chen; Huikai Miao; Zhi Fan Zeng
Journal:  BMC Cancer       Date:  2021-12-14       Impact factor: 4.430

10.  De novo transcriptomic subtyping of colorectal cancer liver metastases in the context of tumor heterogeneity.

Authors:  Seyed H Moosavi; Peter W Eide; Ina A Eilertsen; Tuva H Brunsell; Kaja C G Berg; Bård I Røsok; Kristoffer W Brudvik; Bjørn A Bjørnbeth; Marianne G Guren; Arild Nesbakken; Ragnhild A Lothe; Anita Sveen
Journal:  Genome Med       Date:  2021-09-01       Impact factor: 11.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.